New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
Author:
Publisher
Springer Science and Business Media LLC
Subject
Ophthalmology
Link
http://www.nature.com/articles/s41433-019-0671-0.pdf
Reference96 articles.
1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–90.
2. Schulzer M. Intraocular pressure reduction in normal-tension glaucoma patients. The normal tension glaucoma study group. Ophthalmology. 1992;99:1468–70.
3. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714–20.
4. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13. discussion 829-730
5. Khouri AS, Serle JB, Bacharach J, Usner DW, Lewis RA, Braswell P, et al. Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 Study. Am J Ophthalmol. 2019;204:97–104.
Cited by 55 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Dexamethasone Impairs ATP Production and Mitochondrial Performance in Human Trabecular Meshwork Cells;Current Issues in Molecular Biology;2024-09-05
2. Crystalline keratopathy following long-term netarsudil therapy;American Journal of Ophthalmology Case Reports;2024-09
3. Non-Muscle Myosin II A: Friend or Foe in Cancer?;International Journal of Molecular Sciences;2024-08-30
4. Development of Nitric Oxide-Donating Netarsudil Derivatives as a Synergistic Therapy for Glaucoma with Reduced Ocular Irritation;Journal of Medicinal Chemistry;2024-08-20
5. Adjunctive use of netarsudil 0.02% in the treatment of refractory glaucoma: a one year analysis;International Ophthalmology;2024-07-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3